Bayer Nexavar Safety Profile Fuels Research In Multiple Cancer Indications
Executive Summary
A dual mode of action and favorable safety profile will be the chief selling points for Bayer/Onyx' kidney cancer agent Nexavar (sorafenib), company officials said during Bayer's R&D investor conference in London Dec. 8
You may also be interested in...
Pfizer Oncologic Sutent Will Have Dosing, Slight Price Advantage Over Nexavar
Pfizer's newly approved oncologic Sutent will have a dosing advantage and will be priced at a slight discount compared to Bayer/Onyx' Nexavar
Pfizer Oncologic Sutent Will Have Dosing, Slight Price Advantage Over Nexavar
Pfizer's newly approved oncologic Sutent will have a dosing advantage and will be priced at a slight discount compared to Bayer/Onyx' Nexavar
Bayer/Onyx Nexavar Approved For Broad Advanced Kidney Cancer Indication
FDA's full approval of Bayer/Onyx' kidney cancer therapy Nexavar (sorafenib) covers both refractory and first-line use